Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic Hyperplasia

This publication has 19 references indexed in Scilit:

• Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.
  Journal of Clinical Investigation, 1992
• Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In Vivo
  Seminars in Thrombosis and Hemostasis, 1992
• Sex hormones, lipoproteins, and cardiovascular risk
  Atherosclerosis, 1991
• A Prospective Study of Cholesterol, Apolipoproteins, and the Risk of Myocardial Infarction
  New England Journal of Medicine, 1991
• Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men
  American Journal of Hematology, 1991
• Effects of androgenic steroids on erythropoiesis
  Steroids, 1985
• Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids
  Metabolism, 1984
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
  JAMA, 1984
• Plasma Lipoproteins during Anti-Androgen Treatment by Estrogens or Orchidectomy in Men with Prostatic Carcinoma
  Hormone and Metabolic Research, 1981
• ARE APOLIPOPROTEINS BETTER DISCRIMINATORS THAN LIPIDS FOR ATHEROSCLEROSIS?
  The Lancet, 1979